Gilde Healthcare company Synexa Life Sciences celebrates its 20th anniversary - Gilde Healthcare

Gilde Healthcare company Synexa Life Sciences celebrates its 20th anniversary

March 3, 2023
Leiden & Utrecht (The Netherlands)

Two decades of advancing drug development programs through specialist biomarker and bioanalytical insights

Synexa Life Sciences, a specialist biomarker and bioanalysis services provider, celebrates its 20th anniversary on March the 3rd 2023.

Since its inception in 2003, Synexa Life Sciences has become a trusted partner to pharmaceutical, biotech, academic and non-profit organizations all over the world, helping them to achieve their clinical milestones through the delivery of innovative biomarker and bioanalytical solutions while building a leading reputation for its scientific excellence and expertise.

In recent years, Synexa has invested heavily in staff, equipment and more recently acquisitions – almost tripling its employee headcount, making key additions to strengthen its commercial and scientific team, as well as opening a new laboratory in the USA. With the acquisition of Syrinx Bioanalytics in May 2022, Synexa also gained a Nordic presence and now has global reach with labs in five key locations; London, Berlin, Rockville USA, Turku and Cape Town.

Emile Lens, CEO of Synexa Life Sciences commented: “Our vision is to be the scientific partner of choice for biomarker and bioanalytical solutions, helping our partners to develop drugs and treatments which ultimately improve the quality of human health. Reaching our 20th anniversary milestone is a great achievement, and we are excited to pursue this vision which we have set out for the company.”

Justin Devine, Co-Founder & Chief Innovation Officer at Synexa Life Sciences said: “We would like to thank everyone who has contributed to Synexa’s success in the last two decades, and look forward to continuing to build on this incredible milestone which we have achieved.” Gilde Healthcare, which invested in Synexa in 2019, has been a key partner in the company’s growth and success, providing Synexa with the support needed to scale its business and expand its service offering.

Tom Klein Robbenhaar, Partner at Gilde Healthcare commented: “We are delighted to be celebrating 20 years of Synexa’s success. The company’s commitment to scientific excellence and improving human health has made it a valued partner to pharmaceutical and biotech companies around the world. We look forward to continuing to support Synexa as it enters its third decade of operation.”

About Synexa Life Sciences
For two decades Synexa Life Sciences has supported biopharma clients across the globe to achieve their clinical milestones through the application of cutting-edge biomarker science. Synexa specialises in the development, validation and delivery of a wide range of complex and custom- designed assays, founded on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Synexa is backed by Gilde Healthcare, a leading European healthcare investor.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over $2 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher...
November 20, 2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy...
October 17, 2023